Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS

Table 4 Most frequent selected peaks in the leave-one-out internal validation (LOO) iterations, with the corresponding chip surface and mass range

	Median m/z value	Occurrence*	p-value	Chip surface	Mass range ^§
Lymph node status
Negative vs Positive
	2698.945	15	0.023	IMAC	Low
	15254.808	14	0.022	IMAC	High
	3953.177	13	0.024	CM10	Low
Histological subtype
Squamous ca. vs Adenoca.
	12802.775	28	0.021	CM10	High
	78632.414	11	0.020	IMAC	High
Squamous ca. vs Adenosquamous ca.
	1532.112	39	0.032	CM10	Low
	1532.166	39	0.032	CM10	Low
	1627.269	39	0.032	IMAC	Low
	4783.483	38	0.032	IMAC	Low
Adenoca. vs Adenosquamous ca.
	1531.463	16	0.012	CM10	Low
LVSI
Negative vs Positive
	1741.204	58	0.008	IMAC	Low
	3224.349	13	0.010	CM10	Low
Recurrence
Negative vs Positive
	94029.326	53	0.021	IMAC	High
	97177.269	52	0.018	IMAC	High
	78294.986	52	0.027	IMAC	High
	2044.703	21	0.031	IMAC	Low
	1979.514	15	0.035	IMAC	Low

* The number of times the peak was selected within the different LOO iterations.
§ Low mass range: <10 kDa; high mass range >10 kDa.
Abbreviations: CM10 = weak cation exchanger array; IMAC = immobilized metal affinity capture array; ca. = carcinoma; LVSI = lymph vascular space involvement.

ISSN: 1477-5956